QingSong HealthHKSE:02661 -7.40%18 EBITDA Margin % is 5.66% as of Dec. 2025, which is 69% below its 10-year median of 18.48. GuruFocus rates HKSE:02661 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 664 Healthcare Providers & Services companies, QingSong Health ranks worse than 62.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. QingSong Health's EBITDA for the
six
months ended in Dec. 2025 was HK$37 Mil. QingSong Health's Revenue for the
six
months ended in Dec. 2025 was HK$663 Mil. Therefore, QingSong Health's EBITDA margin for the quarter that ended in Dec. 2025 was 5.66%.
QingSong Health (HKSE:02661) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
QingSong Health EBITDA Margin % Related Terms
QingSong Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for QingSong Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02661 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, QingSong Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QingSong Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, QingSong Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where QingSong Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QingSong Health (HKSE:02661) has a EBITDA Margin % of 5.66% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on QingSong Health and its competitors. This is 69% below median its historical median of 18.48. Over the past decade, QingSong Health's EBITDA Margin % has ranged from 6.22 to 38.75. According to the industry distribution chart, QingSong Health ranks #412 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 62%.
Is QingSong Health's EBITDA Margin % too high?
QingSong Health's current EBITDA Margin % of 5.66% is 69% below median its 10-year median of 18.48. Over the past 10 years, this metric has ranged from a low of 6.22 to a high of 38.75. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. QingSong Health's value of 5.66% is 44.6% below this industry median. Based on the distribution chart, QingSong Health ranks #412 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, QingSong Health has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does QingSong Health's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, QingSong Health ranks #412 out of 664 companies for EBITDA Margin %. This places QingSong Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. QingSong Health's value of 5.66% is 44.6% below this benchmark. Historically, QingSong Health's own EBITDA Margin % has ranged from 6.22 to 38.75 over the past decade. While the company's 10-year median is 18.48 vs. the industry median of 10.21, QingSong Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. QingSong Health's current EBITDA Margin % of 5.66% is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on QingSong Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QingSong Health's current EBITDA Margin % is 5.66%, which is 69% below median its own 10-year median of 18.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QingSong Health stock overvalued right now?
QingSong Health (HKSE:02661) has a current EBITDA Margin % of 5.66%. The current EBITDA Margin % is 5.66%, which is 69% below median its 10-year median of 18.48 and 44.6% below the Healthcare Providers & Services industry median of 10.21. QingSong Health's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For QingSong Health (HKSE:02661), the current EBITDA Margin % is 5.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
QingSong Health Corp is a technology-driven one-stop platform in China, focusing on providing comprehensive health services and health insurance solutions. It offers healthcare-related services, including early disease screening promotion and consultancy, health examinations and consultations, medical appointment services, and the sale of health supplements. It prominently offers health insurance products providing coverage for illness and medical expenses, typically for one year or less. The company also offers critical illness insurance, which provides a lump-sum payment if the policyholder is diagnosed with specified serious illnesses. It derives revenue from the provision of Healthcare-related Services. Geographically, it operates only in China.
18GF Score
Get the complete analysis for HKSE:02661
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02661 has been successfully added to your 